# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate ...
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE...